Cargando…
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
The proto-oncogene c-Src is a non-receptor tyrosine kinase playing a key role in many cellular pathways, including cell survival, migration and proliferation. c-Src de-regulation has been observed in several cancer types, making it an appealing target for drug discovery efforts. Recent evidence emph...
Autores principales: | Belli, Stefania, Esposito, Daniela, Servetto, Alberto, Pesapane, Ada, Formisano, Luigi, Bianco, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352780/ https://www.ncbi.nlm.nih.gov/pubmed/32517369 http://dx.doi.org/10.3390/cancers12061489 |
Ejemplares similares
-
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023) -
What else can we do to prevent diabetic retinopathy?
por: Simó, Rafael, et al.
Publicado: (2023) -
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
por: Santaniello, Antonio, et al.
Publicado: (2019) -
What else did we learn?
por: Pojer, M
Publicado: (2009) -
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
por: Formisano, Luigi, et al.
Publicado: (2015)